If agreeable, you will undergo screening labs and liver imaging as an outpatient.
If you qualify, you will be admitted for a 3-day stay on a later date to start therapy with sofosbuvir/velpatasvir (Epclusa), an FDA-approved medication for the treatment of hepatitis C.
You will be closely monitored on a monthly basis by an NIH liver physician while on therapy.